DeepMed Research

Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Phase 2

Recruiting

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Zanubrutinib Pill
Drug: Venetoclax Pill
Drug: Obinutuzumab Injection

First Posted Date: 2022-12-14

Last Posted Date: 2025-03-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 50

Registration Number: NCT05650723

Locations: 🇺🇸
Weill Cornell Medicine/NewYork-Presberteryian Hospital, New York, New York, United States

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Follicular Lymphoma
Lymphoma, Non-Hodgkin
Diffuse Large B Cell Lymphoma

Interventions: Drug: Venetoclax
Drug: Tazemetostat

First Posted Date: 2022-11-16

Last Posted Date: 2025-04-08

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 38

Registration Number: NCT05618366

Locations: 🇺🇸
Weill Cornell Medicine/NewYork-Presberteryian Hospital, New York, New York, United States

A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients

Phase 2

Recruiting

Conditions: Critical Care
Grief
Trauma
Psychotherapy

Interventions: Other: Supportive Conversation
Behavioral: EMPOWER

First Posted Date: 2022-10-20

Last Posted Date: 2024-11-22

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 172

Registration Number: NCT05587517

Locations: 🇺🇸
NewYork-Presbyterian Weill Cornell Medicine, New York, New York, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Phase 2

Suspended

Conditions: Merkel Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Lutetium Lu 177 dotatate

First Posted Date: 2022-10-18

Last Posted Date: 2024-06-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 18

Registration Number: NCT05583708

Locations: 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

A Preliminary Study for INFORMED

Phase 4

Recruiting

Conditions: Heart Diseases
Heart Failure
Heart Failure, Diastolic
Cardiac Failure
Heart Failure With Preserved Ejection Fraction

Interventions: Drug: Beta blocker

First Posted Date: 2022-10-18

Last Posted Date: 2024-12-12

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 20

Registration Number: NCT05585125

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Engage & Connect: A Psychotherapy for Postpartum Depression

Not Applicable

Recruiting

Conditions: Postpartum Depression

Interventions: Behavioral: Engage & Connect (E&C)
Behavioral: Symptom Review and Psychoeducation (SRP)

First Posted Date: 2022-10-18

Last Posted Date: 2025-04-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 60

Registration Number: NCT05585164

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

HCV Test and Treat Utilizing Simplified HCV Patient Education

Phase 4

Terminated

Conditions: Hepatitis C

Interventions: Diagnostic Test: Cepheid POC HCV Viremia (RNA) test
Other: HCV education from a health care provider
Drug: Glecaprevir and Pibrentasvir

First Posted Date: 2022-10-17

Last Posted Date: 2025-02-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 8

Registration Number: NCT05582681

Locations: 🇺🇸
Phoenix House, Long Island City, New York, United States
🇺🇸
ColumbiaDoctors Midtown, New York, New York, United States
🇺🇸
Weill Cornell Medicine Midtown Center for Treatment and Research, New York, New York, United States

Combination Immunotherapy in Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Neoplasms

First Posted Date: 2022-10-07

Last Posted Date: 2024-08-20

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 36

Registration Number: NCT05571293

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer

Phase 1

Withdrawn

Conditions: Prostate Cancer Metastatic

Interventions: Drug: Actinium-J591
Radiation: Stereotactic Body Radiation Therapy
Drug: Androgen Deprivation Therapy

First Posted Date: 2022-10-05

Last Posted Date: 2023-08-24

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT05567770

Pre-Pilot: Problem Adaptation THerapy in Caregivers

Not Applicable

Withdrawn

Conditions: Caregiver Burden

Interventions: Other: PATH-Care

First Posted Date: 2022-10-05

Last Posted Date: 2025-01-31

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 15

Registration Number: NCT05567120

Locations: 🇺🇸
NewYork-Presbyterian - Weill Cornell Medicine, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy